Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Eur Respir J. 2022 Nov 24;60(5):2201332. doi: 10.1183/13993003.01332-2022. Print 2022 Nov.

Authors

Yang Liu^{1

2}, Hai-Wen Lu^{1

2}, Jin-Fu Xu^{3

2}

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
² Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
³ Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China jfxu@tongji.edu.cn.

PMID: 36137589
DOI: 10.1183/13993003.01332-2022

No abstract available

Publication types

Letter
Comment

MeSH terms

Amphotericin B*
Antifungal Agents / therapeutic use
Aspergillosis, Allergic Bronchopulmonary* / drug therapy
Humans
Recurrence

Substances

liposomal amphotericin B
Amphotericin B
Antifungal Agents